NYSE: CTRECaretrust Reit Inc Stock
$28.06-0.69 (-2.4%)
Updated Apr 21, 2025
CTRE Price
$28.06
Fair Value Price
N/A
Market Cap
$5.27B
52 Week Low
$23.58
52 Week High
$33.15
P/E
34.64x
P/B
1.81x
P/S
14.13x
PEG
0.96x
Dividend Yield
4.29%
Revenue
$296.29M
Earnings
$125.08M
Gross Margin
98.1%
Operating Margin
52.45%
Profit Margin
42.2%
Debt to Equity
0.18
Operating Cash Flow
$244M
Beta
0.7
Next Earnings
Apr 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CTRE Overview
CareTrust REIT, Inc. is a self-administered, publicly-traded real estate investment trust engaged in the ownership, acquisition, development and leasing of skilled nursing, seniors housing and other healthcare-related properties. With a nationwide portfolio of long-term net-leased properties, and a growing portfolio of quality operators leasing them, CareTrust REIT is pursuing both external and organic growth opportunities across the United States.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CTRE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Healthcare Facility REIT
Industry Rating
C
CTRE
Ranked#1 of 16
Ranked#1 of 16
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $66.81 | C | |
| $37.85 | C | |
| $17.79 | C |
Be the first to know about important CTRE news, forecast changes, insider trades & much more!
CTRE News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTRE scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTRE ($28.06) is trading above its intrinsic value of $14.52, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CTRE is poor value based on its earnings relative to its share price (34.64x), compared to the US market average (27.14x)
P/E vs Market Valuation
CTRE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CTRE due diligence checks available for Premium users.
Valuation
CTRE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
34.64x
Industry
106.77x
Market
27.14x
CTRE is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CTRE is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
CTRE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.81x
Industry
2.21x
CTRE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CTRE price to earnings growth (PEG)
For valuing profitable companies with growth potential
CTRE is good value based... subscribe to Premium to read more.
PEG Value Valuation
CTRE's financial health
Profit margin
Revenue
$86.9M
Net Income
$52.1M
Profit Margin
60%
CTRE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.4B
Liabilities
$507.6M
Debt to equity
0.18
CTRE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CTRE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$75.2M
Investing
-$685.6M
Financing
$447.1M
CTRE vs Healthcare Facility REIT Stocks
Caretrust Reit Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.